Pipeline
Pipeline Programs
EB-003
Prescription Model
Highlights
-
Moderate dose
-
Prescription model
-
Taken regularly
-
Minimal side effects and reduced hallucinations
-
Available to a large patient population
Enveric is advancing its EB-003, expected to offer a first-in-class, new approach to the treatment of difficult-to-address anxiety, depression and other disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.
Synopsis of Target Benefits
- Reduced hallucination profile
- Improved cardiac safety
- Orally bioavailable, chronic administration
- Treatment in clinic not required
- Drug intended to be prescribed for regular maintenance and taken at times and in settings more convenient to patient
EVM401
Enveric’s EVM401 series consists of novel phenylalkylamines and indolethylamines, including mescaline-derived compounds, that demonstrate promising interactions with key brain receptors involved in mental health disorders and addiction. Mescaline is a naturally occurring psychedelic alkaloid found in certain cacti, such as peyote and San Pedro, known for its ability to alter perception, cognition, and mood. Early research suggests these compounds may have the potential to help manage opioid withdrawal, attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, and substance use disorders by targeting receptors linked to these conditions.
While Enveric’s primary focus remains on advancing EB-003 toward clinical trials, advancing the EVM401 series reinforces the Company’s commitment to expanding its pipeline and driving innovation in mental health treatment.
